Intarcia announces two presentations at 50th EASD meeting: confirms pivotal phase 3 data announcement for ITCA 650 in type 2 diabetes in 4q
12 September 2014 | By Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15-19...